Acumen Pharmaceuticals, Inc.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$121.3M
- Total assets
- $122.8M
- Market cap
- $155.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $123.8M
- Operating income
- -$123.8M
- Income tax
- $0
- Net income
- -$121.3M
- EPS (basic)
- $-2.00
- EPS (diluted)
- $-2.00
Balance sheet
- Total assets
- $122.8M
- Current assets
- $122.3M
- Total liabilities
- $52.4M
- Current liabilities
- $30.0M
- Shareholders’ equity
- $70.4M
Cash flow
- Operating cash flow
- -$115.5M
- Investing cash flow
- $133.9M
- Financing cash flow
- -$34.0K
- Net cash flow
- $18.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $155.3M
- EPS (diluted)
- $-2.0
- Shares outstanding
- 71.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 1, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $121.3M.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Acumen Pharmaceuticals, Inc..
Write a review
News about Acumen Pharmaceuticals, Inc.
News & sentiment via Polygon.io
